Drug interaction studies between paclitaxel (Taxol) and OC144-093 - A new modulator of MDR in cancer chemotherapy

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2002, Pages 119-126

  Guns, Emma S ^a   Denyssevych, Tetyana ^a   Dixon, Ross ^b   Bally, Marcel B ^a   Mayer, Lawrence ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b Ontogen Corporation   (United States)

Author keywords

Chemotherapy; Cytochrome P450; Human liver microsomes; MDR modulator; OC144 093

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OC 144 093; OC 144-093; PACLITAXEL; CYTOCHROME P450 3A; DRUG; GENE PRODUCT; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; DRUG INTERACTION; DRUG THERAPY; FEMALE; HUMAN; LIVER MICROSOME; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; PHYSIOLOGY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN INTERACTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY; FEMALE; HUMANS; IMIDAZOLES; MICE; MICROSOMES, LIVER; NEOPLASMS; PACLITAXEL; ANIMAL; HUMAN;

EID: 0035987082     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190426     Document Type: Article

References (28)

1. Discovery and Characterization of OC144-093, a novel inhibitor of Pgp mediated MDR
2. P-glycoproteins and multidrug resistance
3. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and Pglycoprotein: Implications for drug delivery and activity in cancer chemotherapy
4. Assessment of the involvement of CYP3A in the in vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-093, by human liver microsomes
5. Variability in human cytochrome P450 paclitaxel metabolism
6. The Biochemistry of P-Glycoprotein mediated multidrug resistance
7. The multi-drug resistance phenotype in human cancer
8. Multi-drug resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites
9. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
10. P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy
11. Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane potential
12. Reversal of multidrug resistance by verapamil analogues
13. The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo
14. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
15. SDZ PSC833, a non-immunosuppressive cyclosporin: Its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia
16. Phase I pharmacokinetic study of Cyclosporin A combined with Doxorubicin
17. The effect of verapamil on the pharmacokinetics of adriamycin
18. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions
19. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
20. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs
21. Hepatic biotransformations of docetaxel (Taxotere") in vitro: Involvement of the CYP3A subfamily in humans
22. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
23. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
24. Tolbutamide 4-hydroxylase activity of human liver microsomes: Effect of inhibitors
25. Human liver microsomal metabolism of paclitaxel and drug interactions
26. Effects of imidazole derivatives on cytochrome P-450 from human hepatocytes in primary culture
27. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers
28. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite